Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.62 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201365 | 0.83 | CLK1 (0.47) | DGAT1CES2ALDH1A1TSHRCA12 | |
| SCHEMBL11015067 | 0.82 | CES2 (0.48) | DGAT1CES2ALDH1A1TSHRCA12 | |
| SCHEMBL3816558 | 0.80 | CES2 (0.46) | DGAT1CES2ALDH1A1TSHRCA12 | |
| SCHEMBL311907 | 0.80 | CA12 (0.61) | CES2ALDH1A1TSHRCA12CA1 | |
| SCHEMBL29758181 | 0.80 | CES2 (0.68) | DGAT1CES2PARP10PARP15ALDH1A1 | |
| SCHEMBL293958 | 0.80 | CES2 (0.68) | DGAT1CES2PARP10PARP15ALDH1A1 | |
| SCHEMBL1805264 | 0.79 | CES2 (0.50) | DGAT1CES2PARP10ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL30628427 | 0.78 | CES2 (0.65) | DGAT1CES2PARP10PARP15ALDH1A1 | |
| SCHEMBL113659 | 0.78 | DGAT1 (0.62) | DGAT1CES2PARP10PARP15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3851067 | 0.78 | CES2 (0.65) | DGAT1CES2PARP10PARP15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056198-A2 | USE OF COMPOUNDS FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO CHONDROCYTES | MSP Co., Ltd (KR) | 2016-08-17 | — | — | EP | claimed |
| EP-2617415-B1 | USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS | CATHOLIC KWANDONG UNIVERSITY INDUSTRY FOUNDATION (KR) | 2016-04-20 | — | — | EP | claimed |
| US-20150252003-A1 | Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells | MSP CO., LTD. (KR) | 2015-09-10 | — | — | US | claimed |
| US-9068166-B2 | Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes | INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) | 2015-06-30 | — | — | US | claimed |
| US-20130236969-A1 | Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2013-09-12 | — | — | US | claimed |
| EP-2617415-A2 | USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2013-07-24 | — | — | EP | claimed |
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | claimed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | claimed |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4186896-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220253-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | DGAT1 3684/4885CES2 1059/4885PARP10 2145/4885 |
| US-20130236969-A1 | Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes | COL2A1, MYADM, COL1A1 | DGAT1 1297/4885CES2 4815/4885PARP10 2508/4885 |
| US-20020151718-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | DGAT1 3684/4885CES2 1059/4885PARP10 2145/4885 |
| US-20150252003-A1 | Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells | COL2A1, MYADM, COL1A1 | DGAT1 1355/4885CES2 4785/4885PARP10 2403/4885 |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | PTPRF, PTPRCAP, PTPRJ | DGAT1 1427/4885CES2 4405/4885PARP10 4293/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | DGAT1 2259/4885CES2 3382/4885PARP10 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.